Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Eyevensys Appoints Dr Ivan Cohen-Tanugi as CEO

Published: Tuesday, March 26, 2013
Last Updated: Tuesday, March 26, 2013
Bookmark and Share
Dr Ivan Cohen-Tanugi, with over 20 years’ experience in the international pharmaceutical industry, will prepare Eyevensys to launch clinical trials for the company’s non-viral gene therapy processes in two ophthalmic indications.

Eyevensys has announced the appointment of Dr Ivan Cohen-Tanugi as CEO.

Having worked for Sanofi, Amgen International, Roche Pharma and Teva Pharmaceuticals, Dr Cohen-Tanugi first plans to conclude Eyevensys’ preclinical tests over the next 12 months. The first human tests are planned within 18 months.

The Eyevensys process is an electrotransfer of plasmids in the ciliary muscle of the eye.

The Eyevensys team is one of a small group that has reached an advanced stage of development of the process using a non-viral approach.

This treatment is less invasive than current treatments. It allows for injections to be administered from either once a fortnight or monthly to once every six months.

This reduces the dose of drugs and proteins, consequently reducing side effects.

The first preclinical results from animal subjects show therapeutic protein expressions for up to nine months. These results have been the focus of articles published in reputed scientific journals.

“I am delighted to have been given the responsibility of leading Eyevensys through to the next stages of its development,” said Dr Ivan Cohen-Tanugi , CEO at Eyevensys.

Dr Cohen-Tanugi continued, “Eyevensys is backed by stable and trusted investors who are very involved in the business’ development. A new financing round is planned for this year. We hope to sign up new stakeholders, notably on an international level, to diversify our support and proceed up to Phase II.”

“Ivan Cohen-Tanugi’s extensive experience in the pharmaceutical and biotechnological fields will contribute to Eyevensys’ ability to move at a faster pace and proceed to the clinical phase in the best possible circumstances,” said professor Francine Behar-Cohen, Eyevensys’s founder and scientific advisor. “Our key goal is to discover proofs of concept for the electrotransfer process in humans.”

The company targets two main indications, where medical needs are currently urgent and unmet:
• Uveitis, an orphan disease, is an inflammation of the uvea (iris, ciliary body and/or choroid). It causes 10 per cent of cases of blindness in Western countries.

• Age-related Macular Degeneration (AMD) is a disease caused by a gradual degeneration of the macula, the central part of the retina, which can appear from age 50 and more frequently from age 65. It causes a significant weakening of visual capabilities, but does not destroy them.

The exact causes of this condition are unknown. No cure has yet been found. Existing treatments can only slow its progression. As much as 12 per cent of the population between ages 65 and 75 have AMD. It is the leading cause of non-correctable blindness in the western world. Due to population aging, its prevalence may increase by nearly 50 per cent by 2020. Worldwide, an estimated 25 million people are affected.

Dr Cohen-Tanugi, aged 51, has more than 20 years of experience in the international pharmaceutical and biotechnological industry. Before joining Eyevensys, he was vice president and general manager of the Biologics and Specialty unit at Teva Pharmaceuticals in the USA.

He has considerable experience in biologics and the pharmaceutical industry on an international level, notably in the fields of sales and marketing, global product launches, R&D team leadership and financing.

He worked in Switzerland for many years for Roche Pharma, then for Amgen International and finally for Teva Pharmaceuticals. Cohen-Tanugi started his career at Sanofi, where he held various positions in France and the USA. He is trained as a doctor and also holds an MBA from the HEC Business School.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Eyevensys Announces an Equity Investment by Boehringer Ingelheim Venture Fund
Dr Michel Pairet, Boehringer Ingelheim's head of non-clinical research and development, joins Eyevensys’ board of directors.
Thursday, April 11, 2013
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
The MaxSignal Colistin ELISA Test Kit from Bioo Scientific
Kit can help prevent the antibiotic apocalypse by keeping last resort drugs out of the food supply.
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Closing the Loop on an HIV Escape Mechanism
Research team finds that protein motions regulate virus infectivity.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos